资讯

Nektar Presents New Data from REZOLVE-AD Phase 2b Study for Rezpegaldesleukin in Late ...

Nektar Therapeutics (Nasdaq: NKTR) today announced new data from the ongoing REZOLVE-AD Phase 2b study of rezpegaldesleukin, ...